Kite -Juno went at high end of valuation as they played in CART - it was based on promise. Look at TESARO - it went for $5 B and it has approved product in the hot market.
So the valuations vary dramatically. Oncology pays highest premium - however look at exel, aveo - both have approved cancer drug and they are not bought out.
So each cancer drug is different and perception of BP matters.
I personally do not think HIV indication will lead to high value of BO more than $4-5 B. Good results that show Pro-140 reduces metastasis in prostate and more in breast cancer may lead to $5-6 B as high end BO, if it at all.
In short, I consider $30 as very high end BO (mc of $12-14 B) as unlikely to happen.
News 
Market Data 
Discover 
